Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, ...

Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

In 2025, Aetna will merge its three stand-alone prescription drug plans into a single plan and member cost-shares will be ...

Reference ustekinumab was originally approved by the FDA in 2009. Wezlana (ustekinumab-auub) was approved last October.

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 ...

VX-880 is an allogeneic stem cell-derived islet cell therapy that has been able to control blood glucose as well as natural ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while ...